Molecular signatures in prostate cancer (PCa) tissue can provide useful prognostic information to improve the understanding of a patient's risk of harbouring aggressive disease.
To develop and validate a gene signature that adds independent prognostic information to clinical parameters for better treatment decisions and patient management.